I agree.
This was published last night in Nature Cancer, "Targeting the innate immune system in pediatric and adult AML."
https://www.nature.com/articles/s41375-024-02217-7
I've rewatched this presentation several times but its making a lot of sense.
https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02710995-69UCCL0B3668NS2PSD1Q0C53O2/pdf?access_token=0007rInP8VKAEnFJfs0cXGTQyMga
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-24
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable